ATOMATAI, INC.

ATOMIC AI

pharmaceutical preparations for the modification of RNA expression and alteration of RNA translation for the treatment of cancers and autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes;AI;research and development of pharmaceuticals, namely, therapies for the modification of RNA expression and alteration of RNA translation, used in the treatment of cancers and autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; research and development in the fields of biotechnology, DNA, RNA, molecules and proteins; automated design and development of biomolecules for medical and scientific use, for use in the manufacture of biosensors, agriculture, synthetic biological research, laboratories and environmental safety and testing; drug design and development featuring machine-learning algorithms and lab automation tools; developing customized software in the field of drug design and development;